Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty

Status Completed

Clinical Trial Summary

Tranexamic acid an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting fibrinolytic activities of plasmin and many studies confirms its effectiveness in decreasing blood loss. The aim of this study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid in adult patients undergoing unilateral total knee replacement.

Clinical Trial Description

Total knee arthroplasty (TKA) is widely used as an effective treatment for end-stage osteoarthritis and other joint diseases of the knee and it improvements in surgical materials and techniques have greatly increased its effectiveness. However, TKA is an orthopaedic surgical method that has a substantial perioperative blood loss.

Classical methods for reducing blood loss and transfusion rate include the use of a pneumatic tourniquet, intraoperative cell saver, hypotensive anesthesia, application of erythropoietin, autologous blood transfusion, plugging of the femoral canal, cementing, drain clamping, navigation and minimally invasive surgery.

Tranexamic acid (TXA) an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting fibrinolytic activities of plasmin has been used as an adjuvant to such measure and many studies with a level of evidence confirms its effectiveness in decreasing blood loss.

Fibrinolysis is stimulated by surgical trauma blood loss and TKA may be related to increased fibrinolytic activity. TXA inhibits fibrinolysis by blocking the lysine-binding sites of plasminogen to fibrin. Plasmin, bound to tranexamic acid, has a considerably diminished activity with respect to fibrin compared to that of free plasmin. Also, it appears from various studies that, in vivo, tranexamic acid at high doses exerts a braking activity on the activation of the complement system. So, TXA reduces bleeding in the TKA and its functional repercussion has also been confirmed in assays for various dosages and routes of administration.

In the literature, efficacy of intra-articular TXA has also been confirmed, but what is the right dosage is now unclear.

The aim of this study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid (Sanofi-Aventis® Gentilly, France). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04085575
Study type	Interventional
Source	Centre Hospitalier de Montauban
Contact
Status	Completed
Phase	Phase 4
Start date	January 1, 2019
Completion date	January 9, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02963623` - Fibtem Predicts Postoperative Bleeding	N/A
Completed	`NCT00307138` - Hetastarch and Bleeding Complications After Off-Pump Coronary Bypass Surgery	Phase 3
Active, not recruiting	`NCT06114758` - Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
Completed	`NCT03793816` - Tonsillectomy Using BiZact™ - a Randomized Side-controlled Clinical Trial	N/A
Terminated	`NCT05308589` - CPPF After General Cardiac Surgery	N/A
Completed	`NCT04505475` - Oral Surgery in Patients Taking Direct Oral Anticoagulants
Completed	`NCT05229276` - Efficacy of Sternum Guard in Post Cardiac Surgery Patient	N/A
Completed	`NCT05817474` - Efficacy of Local Infiltration of Tranexamic Acid and Lidocaine in Tonsillar Bed on Postoperative Bleeding and Pain During Tonsillectomy Surgery: Prospective, Randomized, Control Study	N/A
Terminated	`NCT02343263` - Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage	Phase 2
Not yet recruiting	`NCT06285656` - Femoral Blood Gas and Prediction of Postoperative Bleeding
Recruiting	`NCT04725305` - BiZact Tonsillectomy in the Pediatric Population	N/A
Recruiting	`NCT05889494` - Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients	N/A
Not yet recruiting	`NCT06450834` - Ostene in Thoracolumbar Decompression and Fusion Evaluated With VIBE
Recruiting	`NCT01889732` - A Gray Zone Approach of Rotational Thromboelastometry for Predicting Postoperative Bleeding in Cardiac Surgical Patients	N/A
Completed	`NCT00337766` - Desmopressin in Cardiac Surgery	Phase 4
Completed	`NCT00587444` - Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass	Phase 3
Completed	`NCT06238739` - Optimal Temperature Control in Body Contouring Procedures	N/A
Recruiting	`NCT02709460` - Lateral Occlusion of Uterine Artery in Total Laparoscopic Hysterectomy	N/A
Completed	`NCT02627560` - The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy	Phase 4
Terminated	`NCT02358850` - Post-tonsillectomy Pain Control in Adults	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.